Alfa Wassermann launches APR’s OTC Diclofenac

Dicloreumdol® is now available in Italy, promoted and commercialized by the leading Italian pharmaceutical company Alfa Wassermann.

Dicloreumdol® is a new tablet product containing Diclofenac – a proven nonsteroidal anti-inflammatory drug (NSAID). It is based on the APR’s patented Dynamic Buffering Technology (DBT) that secures faster pain relief in common acute conditions. This technology includes a unique blend of Diclofenac and bicarbonate that creates a suitable microenvironment at gastro-intestinal level, avoiding precipitation of acid Diclofenac in the gastric environment and thus allowing a fast absorption and prompt onset of analgesic action without affecting overall tolerability and safety.

“With this latest launch, Alfa Wassermann OTC Business Unit Division aims to strengthen its position and enlarge its pain relief product portfolio in the body pain self-medication market – states Marco Torriglia Alfa Wassermann OTC Business Unit director. That’s why we decided to support Dicloreumdol® promotion and invest in an advertising campaign.”

We are proud of this launch in Italy in partnership with Alfa Wassermann. – said Paolo Galfetti, Chief Executive Officer of APR – APR’s Diclofenac drugs, including DBT based ones, are currently marketed and promoted in several countries all over the world, thanks to a wide network of partners, such as Novartis AG as well as Depomed for US market and Canada. Approximately 100 million doses of APR’s Diclofenac DBT are sold every year, confirming the distinctive and exclusive competitive advantage of APR’s formulation over conventional preparations.”

2016-12-13T00:19:36+00:00 Applied Pharma Research (APR)